Full history for every metric is available with a Kvantra account
Regeneus Ltd (RGS.AX)
Key financial summary
Financials in AUD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 1 | 0 | 2 | 7 | 0 | 0 | 0 |
| Operating profit | AUD m | -2 | -3 | |||||
| Net profit | AUD m | -5 | -6 | -4 | 2 | -4 | -2 | -2 |
| EPS reported | AUD | -0.01 | -0.01 | |||||
| Operating cashflow per share | AUD | -0.00 | -0.00 | |||||
| Capex per share | AUD | 0.00 | 0.00 | |||||
| FCF per share | AUD | -0.00 | -0.00 | |||||
| Free cash flow | AUD m | -1 | -0 | |||||
| Net debt | AUD m | 2 | -0 | |||||
| Book value equity | AUD m | -2 | -1 | |||||
| Book value per share | AUD | -0.01 | -0.00 | |||||
| Number of shares | m | 306.44 | 306.44 | |||||
| DPS (TTM paid) | AUD | 0.00 | 0.00 |
Financial summary
Financials in AUD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -1.18 | -3.35 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -3.25 | -7.81 | |||||
| EV/EBITDA LTM | x | -1.64 | -1.42 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -78.64% | -45.87% | |||||
| FCF Yield | % | -30.79% | -12.80% | |||||
| Quality | ||||||||
| ROE | % | 92.94% | 455.81% | |||||
| ROIC | % | 96.69% | 96.69% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | -100.00% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.34 | - | |||||
| Net Debt/EBITDA | x | -0.71 | -0.71 | |||||
| EBIT/Net interest | x | -6.42 | -6.42 | |||||
| Net debt/market cap | % | 76.65% | -0.74% | |||||
| Net debt/Equity | x | -0.91 | 0.02 | |||||
| Gross debt/equity | x | -1.07 | -0.00 | |||||
Company overview
Regeneus Ltd is an Australian clinical-stage company focused on regenerative medicine, creating cell-based treatments for various human health conditions. Its primary areas of research include osteoarthritis, a range of other musculoskeletal ailments, neuropathic pain, and dermatological disorders. The firm's leading platform technology, Progenza, offers a multi-synergistic therapy for addressing both osteoarthritis and neuropathic pain. Additionally, Regeneus is developing Sygenus, which targets the healing of skin wounds. Founded in 2007, the company's headquarters are located in Paddington, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Regeneus Ltd (RGS.AX)
Regeneus Ltd is an Australian clinical-stage company focused on regenerative medicine, creating cell-based treatments for various human health conditions. Its primary areas of research include osteoarthritis, a range of other musculoskeletal ailments, neuropathic pain, and dermatological disorders. The firm's leading platform technology, Progenza, offers a multi-synergistic therapy for addressing both osteoarthritis and neuropathic pain. Additionally, Regeneus is developing Sygenus, which targets the healing of skin wounds. Founded in 2007, the company's headquarters are located in Paddington, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free